Japan Multiple Sclerosis Therapeutics Market Report 2023 to 2030

Japan Multiple Sclerosis Therapeutics Market Analysis

$ 3999

Japan multiple sclerosis therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The prevalence of multiple sclerosis (MS) is rising, and funding for MS research is rising as well. These are the two reasons propelling market expansion. Major global players in this market are Abbott (U.S.), Bristol-Myers Squibb Company (U.S.), Teva Pharmaceutical Industries Ltd (Israel), Takeda Pharmaceutical Company Limited (Japan), Jazz Pharmaceuticals, Inc. (U.K.), Novartis AG (Switzerland), Biora Therapeutics, Inc. (U.S.), Bausch Health Companies Inc. (Canada), Pfizer Inc. (U.S.), Novartis AG (Switzerland), Mylan N.V. (U.S.)

ID: IN10JPRD047 CATEGORY: Rare Diseases GEOGRAPHY: Japan AUTHOR: Sakshi Mantri

Buy Now

Japan Multiple Sclerosis Therapeutics Market Analysis Summary

Japan Multiple Sclerosis Therapeutics Market is valued at around $1.59 Bn in 2022 and is projected to reach $2.24 Bn by 2030, exhibiting a CAGR of 4.4% during the forecast period 2023-2030.

A chronic, inflammatory immune-mediated disease called multiple sclerosis (MS) can result in demyelination, neurodegeneration, and axonal transection of nerve cells in the spinal cord and brain. Antidepressants, infused, oral, and injectable medications, physical therapy, and muscle relaxants are a few of the treatments that are regularly used. The prevalence of multiple sclerosis (MS) is rising, and funding for MS research is rising as well. These are the two reasons propelling market expansion. Major global players in this market are Abbott (US), Bristol-Myers Squibb Company (US), Teva Pharmaceutical Industries Ltd (Israel), Takeda Pharmaceutical Company Limited (Japan), Jazz Pharmaceuticals, Inc. (UK), Novartis AG (Switzerland), Biora Therapeutics, Inc. (US), Bausch Health Companies Inc. (Canada), Pfizer Inc. (US), Novartis AG (Switzerland), Mylan N.V. (US)

Market Dynamics

Market Growth Drivers

Increasing Incidence of Multiple Sclerosis: In the world, multiple sclerosis is now more prevalent. According to a study by the National Multiple Sclerosis Society, there were an estimated 1 million persons in the US who had multiple sclerosis in 2017. In 2010, there were recorded 727,344 adult cases of multiple sclerosis, with a disease rate of about 309 cases per 100,000 people. According to the Canadian government, there were more than 77,000 Canadians with multiple sclerosis who were still alive. According to the Multiple Sclerosis Society, 110,000 people in the UK have multiple sclerosis as of 2018. In addition, women are more likely than men to be diagnosed with MS. Every year, there are more new patients receiving diagnoses
Increased Organizational R&D Activities

Developments of Japan Multiple Sclerosis Therapeutics Market

The US FDA gave Ponvory the green light in 2021 for Janssen. This once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator is approved for use in adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

In 2020, Novartis announced that the US FDA has authorized Kesimpta®, an injection for subcutaneous usage, for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive illness in adults.

Key players

Biogen Novartis Sanofi Roche EMD Serono Acorda Therapeutics Teva Pharmaceutical Industries Actelion Catalyst Biosciences uniQure

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Japan Multiple Sclerosis Therapeutics Market Segmentation

By Route of Administration

Oral
Injectable
Intravenous

By Treatment

Immunosuppressants
Humira
Infliximab
Immunomodulators
Thalidomide
Lenalidomide

By End-user

Hospital and Clinics
Diagnostic Laboratories
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.